by Rod Raynovich | Jul 20, 2010 | 2023-24 Life Science Portfolios, BIOgraph
Gilead (GILD) Down on Missed Estimates-Is the Worst Finally Over for the Stock? Despite its stock being down over 30% from Q1 highs and earnings downgrades in April as a fallout from healthcare reform, the Company still disappoints Wall Street with Net Income of...